



Received on 05 May, 2017; received in revised form, 26 July, 2017; accepted, 11 August, 2017; published 01 January, 2018

CLINICAL UPDATES ON DRUG - INDUCED CARDIOTOXICITY

Ashif Iqbal¹, Syed Ehtaishamul Haque^{*2}, Sumit Sharma², Mohd. Asif Ansari², Vasim Khan² and Mohammad Kashif Iqbal³

Translam Institute of Pharmaceutical Education and Research¹, Mawana Road, Meerut - 250001, Uttar Pradesh, India.

Department of Pharmacology², Department of Pharmaceutics³, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, Delhi, India.

Keywords:

Anthracycline,
Interferon- α , Tricyclic
antidepressant, Arrhythmia,
Left ventricular dysfunction,
Oxidative stress

Correspondence to Author:

Dr. Syed Ehtaishamul Haque


Assistant Professor,
Department of Pharmacology,
School of Pharmaceutical Education
and Research, Jamia Hamdard
(Hamdard University), New Delhi -
110062, Delhi, India.

E-mail: haquepharm@gmail.com

ABSTRACT: Cardiotoxicity associated with the clinically used drugs is a global concern of safety for healthcare professionals. Various animal models have been used to study the drug-induced cardiotoxicity but the exact molecular involvement of toxicity is not much clear. Despite the recurrent occurrence of toxicities, drugs such as doxorubicin, calcium channel blockers, antiarrhythmics and immunomodulators are regularly used. Anticancer drugs mainly anthracyclines, 5- fluorouracil and cyclophosphamide exert prominent cardiotoxicity. Till date, there is only one drug approved for doxorubicin-related cardiotoxicity *i.e.* dexrazoxane. Few other drugs are used routinely by clinicians to reduce the severity of toxicity which includes ACE inhibitors, L-carnitine, probucol, CoQ₁₀, N-acetylcysteine, Vitamin E and deferoxamine, whereas antidepressants drugs, specifically tricyclic antidepressants are potential candidates for cardiotoxicity. Calcium channel blockers, antiarrhythmic and beta receptor antagonist aggravate cardiac heart failure (CHF) and left ventricular arrhythmia. Interferons, mainly interferon- α is also associated with prominent and dose-dependant toxicity. Some other drugs like zidovudine, chloroquine, cocaine, minoxidil, ketoconazole, prostaglandin E2 and anagrelide are also reported to have cardiotoxic effects. A complication associated with the use of these drugs include hypoxia, coronary ischemia, calcium overload, oxidative stress, contractile dysfunction, left ventricular arrhythmia and cardiomyopathy.

INTRODUCTION: Cardiotoxicity is the common side effect of many drugs¹ among which anticancer drugs, specifically anthracycline class of drugs exert severe cardiotoxicity². Other drugs that cause cardiotoxicity are amphetamine, mitomycin, paclitaxel and zidovudine^{3, 4}. The common mechanism leading to cardiotoxicity is oxidative stress, generation of free radicals and hypoxia⁵.

Long-term exposure to cardiotoxic drugs further causes apoptosis and deregulation of myo- contractility. Cardiotoxic effect of drugs can be understood in two ways. (1) Drugs causing cardiac injury by affecting the performance of cardiac muscles. (2) By altering the ion channels and pump (voltage-gated sodium and potassium ion channel and Na⁺ - K⁺ ATPase pump)⁴. Exposure to the cardiac-toxic drugs induces prolong cardiac repolarization (QT interval) and causes arrhythmia (Torsades de pointes)⁴. Since these drugs causes cardiotoxicity as side effect, they can be used as cardiotoxicity inducing agents in preclinical experimental models⁶. In this review we are going to focus on the Cardiotoxicity of drugs only and not the experimental models.

QUICK RESPONSE CODE 	DOI: 10.13040/IJPSR.0975-8232.9(1).16-26
	Article can be accessed online on: www.ijpsr.com
DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.9(1).16-26	

List of cardiotoxic drugs is shown in **Table 1** and effect of cardiotoxic drug is displayed in **Fig. 1** ⁷.




FIG. 1: EFFECT OF CARDIOTOXIC DRUGS ON HEART THROUGH DIFFERENT MECHANISMS

TABLE 1: LIST OF CLINICALLY USED DRUGS THAT EXERT CARDIOTOXIC EFFECT ⁸

S. no.	Drug	Class	Mode of action	Use
1	Doxorubicin	Anticancer	Inhibit progression of topoisomerase II	Breast cancer, bladder cancer, lymphoma, Kaposi's sarcoma.
2	Daunorubicin	Anticancer	Inhibit progression of topoisomerase II	Kaposi's sarcoma, lymphoma, myelogenous leukemia
3	Idarubicin	Anticancer	Inhibit progression of topoisomerase II	Acute myeloid leukemia.
4	Cyclophosphamide	Anticancer	Bind at 7 guanine residue and inhibit cell division	Lymphoma, multiple myeloma, ovarian, breast and lung cancer.
5	5 fluorouracil	Anticancer	Thymidylate synthase inhibitor, inhibit DNA replication.	Colon, stomach, esophageal, pancreatic, breast and cervical cancer
6	Chloroquine	Antimalarial	Prevent biocrystallization of hemozoin	Arthritis, malaria, lupus erythematosus
7	Cocaine	Stimulant	Inhibit MAO uptake	Numbing agent
8	Cytarabine	anticancer immunosuppressant	Inhibit DNA and RNA polymerase	AML, CML and non-Hodgkin's lymphoma
9	Paclitaxel	Anticancer	Act on tubulin and causes instability of cytoskeleton causes cell cycle arrest	kapski sarcoma, ovarian, breast, lung, cervical, and pancreatic cancer
10	Mitomycin	Anticancer	Inhibit DNA cross linking	Adenocarcinoma, anal, bladder, breast, cervical, colorectal and lung cancer.
11	Imatinib	Anticancer	Tyrosine kinase inhibitor	CML, gastrointestinal stromal tumors, plexiform neurofibromas.
12	Sunitinib	Anticancer	Tyrosine kinase inhibitor	Renal cell carcinoma and gastrointestinal stromal tumors.
13	Trastuzumab	Monoclonal antibodies	Act through PI3K/Akt pathway	Breast cancer
14	Zidovudine	Antiretroviral	Inhibit HIV's reverse transcriptase enzyme	HIV and HAART

15	Mitoxantrone	Anticancer	Topoisomerase II inhibitor	Metastatic breast cancer, acute myeloid and lymphoblastic leukemia
16	Stibogluconate	Antileishmanial	Topoisomerase I inhibitor	Leishmaniasis
17	Minoxidil	Antihypertensive	Potassium channel opener	Alopecia, hypertension
18	Calcium channel blocker	Antihypertensive	Block calcium entry into cell	Control heart Beat and prevent cerebral vasospasm
19	Interferon	Signaling protein	activate JAS-STAT and PI3K/ Akt pathway	Autoimmune disorder, cutaneous, hairy and myeloid leukemia, hepatitis C
20	Cyclosporine	Immunosuppressant	Inhibit the phosphatase activity of calcineurin	Graft rejection, rheumatoid arthritis, psoriasis, UC and dry eye
21	Bromocriptine	Dopamine agonist	Inhibit the release of glutamate	Pituitary tumor, hyperprolactinemia, PD, type-2 diabetes
22	Methylphenidate	CNS stimulant	Dopamine reuptake inhibition	Bipolar disorder and major depressive disorder
23	Amphetamine	CNS stimulant	Enhances dopaminergic activity and inhibit MAO transport	Attention deficit hyperactivity syndrome, narcolepsy, depression
24	Methamphetamine	CNS stimulant	Enhances dopaminergic activity and inhibit MAO transport	Attention deficit hyperactivity syndrome, narcolepsy, obesity and depression
25	Anabolic steroid	Anabolic-androgenic steroid	Binds to the androgenic receptor & initiate anabolism cascade	Bone marrow, growth and appetite stimulant, male contraception, HRT
26	Clozapine	Atypical antipsychotic	Bind with dopamine and serotonin receptor	Psychosis, schizophrenia and parkinsonism
27	Anagrelide	Platelet reducing agent	Inhibit maturation of platelets from megakaryocytes	Essential thrombocytosis and chronic myeloid leukemia.
28	Tricyclic antidepressant	Antidepressant	Block serotonin and norepinephrine transport	Depressive disorder and dysthymia
29	Ephedrine	Adrenergic stimulant	Stimulate adrenergic receptor and increase activity of norepinephrine	Antihypertensive, spinal anesthesia, asthma, nasal congestion and obesity
30	Catecholamine	Neuromodulator	Stimulate adrenergic receptor and increase activity of norepinephrine	Bradycardia, hypotension and hypoglycemia
31	Isoproterenol	Non-selective beta-adrenoreceptor agonist	Stimulate adrenergic receptor	CHF, shock, treatment of airway constriction and bradycardia
32	Pentamidine	antimicrobial	Interfere with host DNA, RNA, protein and phospholipid synthesis	Leishmaniasis, babesiosis and pneumocystis pneumonia.
33	Ethanol	Addictive psychoactive	Bind with GABA and increases the activity	Antiseptic, antidote and medicinal solvent.
34	Arsenic	Heavy metal	Interfere with host DNA, RNA, protein and phospholipids synthesis	In antibiotics, syphilis and trypanosomiasis
35	Cobalt	Heavy metal	Interfere with host DNA, RNA, protein and phospholipids synthesis	Radiation treatment, metabolism regulator and cofactors.
36	Diazoxide	Potassium channel activator	Increase permeability to potassium ion, modulate AMPA and kainate receptor	Malignant hypertension and insulinoma.
37	NSAIDs	COX inhibitor	Non-selective inhibitor of COX enzyme	Analgesic, antipyretic and anti-inflammatory
38	Interleukin-2	cytokines	Stimulate and growth of T cell, release histamine, anti-inflammatory activity	Autoimmune disorder
39	Ketoconazole	Antifungal	Interfere with the fungal ergosterol synthesis and some enzymes	Athlete's foot, ringworm, candidiasis, and other fungal infection
40	Prostaglandin E2	oxytocics	Activate Wnt signaling pathway	Termination of pregnancy and labor induction.
41	Ifosfamide	anticancer	Bind at 7 guanine residue and inhibit of cell division	Testicular, bladder, cervical, ovarian, lung and soft tissue cancer, sarcoma and osteosarcoma.

MAO: Monoamine oxidase, AML: Acute myeloid leukemia, CML: Chronic myeloid leukemia, HAART: highly active antiretroviral therapy, UC: ulcerative colitis, PD: Parkinson's disease, HRT: Hormonal replacement therapy, CHF: Congestive heart failure, COX: cyclooxygenase

1. Anthracycline and Cardiotoxicity: Anthracycline class of drugs are the first line anticancer drugs but their usage are limited due to cardiotoxicity⁹. Doxorubicin (adriamycin) and daunorubicin (daunomycin or rubidomycin) are two members of anthracycline group¹⁰. These two drugs are obtained from actinobacteria '*Streptomyces peuceitius*'¹¹. Anthracycline-induced cardiotoxicity can be acute which may cause arrhythmia, myocarditis, pericarditis or acute left ventricular failure. These symptoms subside just after withdrawal of treatment but restrict the further use of the drug¹².

Anthracycline can also cause cardiomyopathy on the chronic use and sometime late-onset of severe arrhythmia and ventricular dysfunction has been seen¹². It has been observed that rate of survival with anthracycline is much lesser than those of ischemic or dilated cardiomyopathy¹³. Doxorubicin induced cardio-toxicity is dose dependent and controlled monitoring of dose is the best possible way to prevent toxicity¹³. Now-a-days echocardiography is used to monitor doxorubicin-induced cardiotoxicity and this is considered as gold standard test¹⁴.

1.1 Mechanism of Anthracycline - Induced Cardiotoxicity: Generally, chemotherapeutic drugs induced cardiotoxicity is associated with the myocardial cell loss, apoptosis or necrosis which may be mediated by oxidative stress directly or indirectly¹⁵. In practice, determination of exact mechanism of doxorubicin-induced cardiotoxicity is not possible because most of the time patient are on multiple therapies^{16, 17}. There are four hypothesis proposed on the subject of anthracycline-induced cardiotoxicity¹⁸.

(a) Iron and free radical theory in which occurrence of high oxidative stress and depletion of endogenous antioxidant is observed. Myocardium mitochondria are the central point of oxidative stress¹⁸.

(b) Metabolic hypotheses in which C-13 alcoholic metabolite of anthracycline acts on the myocardium and hamper the myocardial energy pathway and intracellular calcium concentrations¹⁸.

(c) Unifying hypothesis in which C-13 alcoholic metabolite is further acted by oxidative stress which results in increased calcium concentration at

the interior of myocardial fiber and damages the cell. This may further enhance the lipid peroxidation and loss of selective membrane permeability¹⁸.

(d) Apoptosis hypothesis in which there is upregulation of pro-apoptotic markers like Bax, caspase and cytochrome c, whereas downregulation of anti-apoptotic markers like Bcl-2, Akt, and PIKT3 pathway¹⁸.

Keeping all these theories in view, the role of free radicals occupy the central position. It has been hypothesized that the oxidative stress not only causes myocardial death but directly affects excitation-contraction properties of cardiac muscles^{9, 19}. Free radicals mainly nitrite free radicals are the major culprit of oxidative stress²⁰.

1.2 Cardioprotective Agents Against Anthracycline - Induced Cardiotoxicity: Drugs used clinically for prevention of anthracycline (doxorubicin) induced toxicity are shown in **Table 2**.

TABLE 2: CLINICALLY USED DRUGS FOR PREVENTION OF ANTHRACYCLINE - INDUCED TOXICITY^{21, 22}

S. no	Drugs
1	ACE inhibitors: systolic heart failure (first line therapy)
2	Dexrazoxane: approved drugs for anthracycline-induced cardiotoxicity
3	L-carnitine
4	Probucol
5	CoQ ₁₀
6	N-acetylcysteine
7	Vitamin E
8	Phenethylamine
9	Deferoxamine

Unfortunately, none of the drugs till date is clinically established as a cardioprotective agent against anthracycline (doxorubicin - induced toxicity)²².

2. Cyclophosphamide and Cardiotoxicity: Cyclophosphamide is an alkylating agent that acts on 7 guanine residue²³. The active metabolite of cyclophosphamide is responsible for anticancer activity²⁴. However, cardiomyopathy which is likely to be diagnosed within 2 weeks of therapy is reported as a side effect⁴. Cardiotoxicity of cyclophosphamide is due to the effect of toxic metabolite on endothelial cells that causes severe

myopericarditis and myocardial necrosis²⁵. If a patient suffers from congestive heart failure (CHF) and get exposed to cyclophosphamide, there is a high chance of death within two weeks²⁶. In an in-clinic study, 19 women suffering from metastatic breast cancer were given cyclophosphamide at low dose with continuous infusion for 96 hours. It was observed that low dose for the longer duration of therapy increased the therapeutic response and chance of developing CHF²⁶.

3. Paclitaxel and Cardiotoxicity: Paclitaxel belongs to taxane class of drugs that act by promoting the polymerization of tubulin²⁷. Thus microtubule formed due to the activity of paclitaxel is unstable and interfere with the cell division at the interphase of the cell cycle. This interference finally leads to cell death²⁷. Paclitaxel is the choice of drug in ovarian and breast cancer^{28, 29}. Asymptomatic bradycardia is most common side effect³⁰. 29% of patients undergoing paclitaxel therapy are likely to suffer from bradycardia^{31, 32}. In a study, combined therapy of doxorubicin with paclitaxel induces CHF in six patients out of³³. This occurrence of 18% CHF in patient raised a valid question for combined therapy of paclitaxel and doxorubicin³³.

4. Mitoxantrone and Cardiotoxicity: Mitoxantrone is structurally similar to doxorubicin³⁴. This drug is reported to be associated with left ventricular heart failure³⁵. In a study when mitoxantrone was used in 805 patients, 1.5% of patient developed CHF, whereas another 1.5% of the patient showed decreased left ventricular ejection fraction³⁶. In conclusion, mitoxantrone has potential to induce cardiotoxicity and caution must be taken while using it.

5. Antimetabolite [5-fluorouracil (5-FU), cytarabine and Capecitabine] and Cardiotoxicity: Among all antimetabolites, 5-FU is most extensively studied drugs in term of cardiotoxicity³⁷. It has a direct effect on myocardial cells and on endothelial cells³⁸. Mononuclear inflammations and myocardial necrosis have been observed in a patient who died from myocardial infarction followed by 5-FU therapy³⁹. 5-FU also induces myocardial hypoxia, CHF and dilated cardiomyopathy have been reported³⁹. Capecitabine, on the other hand, causes ischemia⁴⁰ and cytarabine has been reported for pericarditis⁴¹.

Thus looking into features and shortcomings of these anticancer drugs, some newer drugs have been developed with the aim of targeted therapy⁴². These drugs may offer an advantage in terms of selectivity for cancer cells and less systemic toxicity⁴². Some of these drugs are trastuzumab, imatinib and bevacizumab^{43 - 44}. Some of the targeting newer drugs also showed cardiotoxicity e.g., tyrosine kinase inhibitor (sunitinib and imatinib) have been reported with CHF and hypertension⁴⁵.

6. Antidepressant Drugs and Cardiotoxicity: In today's scenario, depression is getting common etiology in most of the chronic disorders⁴⁶. More often antidepressant drugs are used by clinicians⁴⁷, which are of 3 major classes (1) tricyclic antidepressant (TCA) (2) selective serotonin reuptake inhibitor (SSRIs) and (3) monoamine oxidase inhibitor (MAO inhibitors)²⁶. Among these three classes of drugs, with TCA such as (amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline protriptyline and trimipramine), the related cardiotoxicity is more common⁴⁸. Nearly 20% of the patient often suffers from postural hypotension⁴⁹. This side effect becomes more severe when the patient has existing cardiac comorbid complications⁵⁰. There are reports of altering atrioventricular conduction⁵¹. A possible mechanism was supposed to be a prolongation of the duration of QRS interval⁵². Sudden death has also been reported with the use of antidepressant drugs⁵³. TCA is extensively concentrated in the myocardium⁵⁴ and it causes cardiotoxicity by interfering with reuptake of adrenergic amines⁵⁵, altering myocardial membrane permeability⁵⁵ and by direct action on myocardial⁵⁵. Finally, TCA leads to altered cardiac rhythm and myocardium contractility⁵⁵. There are published evidence of CHF with a number of TCA⁵⁶. On the other hand, SSRIs are related with a lesser incidence of cardiac side effect⁵⁷. Although few study has been performed on the cardio-toxicity of SSRIs⁵⁸.

7. Calcium Channel Blockers and Cardiotoxicity: Calcium channel blockers (CCBs) are one of the extensively used drugs in cardiac complications, mainly in angina pectoris⁵⁹. There is an area of debate on the use of CCBs in patients with existing left ventricular dysfunction⁶⁰. Clinically used CCBs are classified into three groups²⁶.

(1) Phenylethylamine viz. verapamil. (2) dihydropyridines viz. nifedipine, and (3) benzothiazepines viz. diltiazem²⁶. There is a report of cardiotoxicity with the use of CCBs which include negative inotropic effect, activation of rennin-angiotensin system and alteration in membrane calcium transport⁶¹. There is always a high chance of marked hemodynamic alteration in patients of CHF taking CCBs⁶². In a multicentre diltiazem post-infarction trial (MDPIT), risk of CHF was found to be increased⁶³. It has been seen clinically that the chronic use of nifedipine in a patient of existing CHF exert deleterious effects⁶⁴.

8. Antiarrhythmic drugs and Cardiotoxicity:

Adverse effect related to antiarrhythmic drugs is related to its cardio depressant and negative inotropic effect⁶⁵. If the patient is already suffering from left ventricular dysfunctions, antiarrhythmic drugs can further worsen the situation⁶⁶. Negative inotropy of drugs vary from class to class, as class III antiarrhythmic drugs are devoid of negative inotropy⁶⁷. Antiarrhythmic drugs induced negative inotropy is regulated by an alteration in intracellular calcium concentration⁶⁸. There are randomized double blinded placebo controlled trials which showed the increased risk of CHF in the patients who were taking antiarrhythmic drugs⁶⁹. Thus it can be concluded that almost all antiarrhythmic drug have potential to exert a negative inotropic effect, therefore, utmost caution and monitoring is required while using antiarrhythmic drugs⁶⁵.

9. Beta - Adrenoceptor Antagonist and Cardiotoxicity:

Beta - Adrenoceptor antagonists are commonly known as beta blockers. These drugs cause negative chronotropic and inotropic effects and exacerbate CHF⁷⁰. Interestingly when beta blocker was used topically for treatment of glaucoma, it additionally caused CHF⁷¹. In an epidemiological study, no association between the use of topical beta blockers and CHF was found⁷². Similarly, a trial with carvedilol revealed the reduced mortality in patients suffering from CHF²⁶. Thus in order to control beta blocker induced cardiotoxicity (CHF), the initial dose should be low and can be gradually increased²⁶.

10. Interferon and Cardiotoxicity: There are three types of interferon used clinically *i.e.*

interferon alpha, beta and gamma⁷³. Interferon-alpha has been reported with a cardiotoxic effect which includes hypertension and arrhythmia starting from 1st day of treatment⁷⁴. It has been reported that almost 5 - 15% of patients suffer from interferon-mediated cardiotoxicity⁷⁵. Other cardiotoxicities of interferon include cardiomyopathy and cardiac ischemia⁷⁶. The possible mechanism proposed for the interferon alpha - induced cardiotoxicity is hypoxia, interference with energy metabolism and increased oxygen demand⁷⁷.

11. Interleukin-2 (IL-2) and Cardiotoxicity: IL-2 is an approved drug for the treatment of metastatic renal cell carcinoma. IL-2 is associated with deleterious cardiovascular side effects⁷⁸. Reversible left ventricular dysfunction, tachycardia and hypotension are more often reported with the use of IL-2⁷⁸. Use of IL-2 initiates the production of cytokines which further affect myocardium contractility⁷⁸.

12. Amphetamines / Methamphetamines and Cardiotoxicity:

Amphetamine class of drugs are the common drugs used by athletes and often associated with doping⁷⁹. These drugs act centrally and cause stimulation which includes euphoria, intensifies emotions and increases sexuality⁸⁰. This drug enhances neuronal reuptake of norepinephrine, serotonin and dopamine⁸¹. A clinical study has reported the incidence of acute coronary syndrome in 25% of patients taking these drugs⁸². Methamphetamine is reported to be associated with 18% and 40% of incidence of cardiomyopathy^{83, 84}. Similarly, in other clinical study methamphetamine is associated with the incidence of 40% cardiomyopathy⁸⁴. There was an animal study which supported the fact that repeated administration of methamphetamine caused cardiac hypertrophy, necrosis, myocarditis, inflammation, left ventricular dysfunction and left ventricular dilatation⁸⁵. Amphetamine and methamphetamine when administered metabolize into catechol that further causes oxidative stress and cardiomyopathy⁸⁶.

13. Cocaine and Cardiotoxicity: Cocaine is an alkaloid obtained from *Erythroxylon coca* which is a native plant of South America⁸⁷. Initially, it was used as a local anaesthetic but later its use as an ingredient in cola drink started⁸⁸. Pharmacology of

cocaine consists of inhibition of catecholamine uptake by dopamine and norepinephrine transporter at the pre-synaptic neurons. This results in the accumulation of catecholamines at the postsynaptic neuron⁸⁹ which causes increased psychomotor and sympathetic activity⁸⁹. Cocaine also causes the release of norepinephrine and epinephrine from the adrenal medulla that result in severe vasoconstriction⁸⁹. Use of cocaine is associated with myocardial ischemia or myocardial infarction⁹⁰. Cocaine also causes tachycardia and increases systolic - diastolic blood pressure⁹¹. Chronic use of cocaine causes vasoconstriction of coronary artery and thrombosis which together decreases oxygen supply to the myocardium and induces myocardial ischemia⁹¹. Acute administration of cocaine causes an increase in intracellular calcium concentration and stimulates arrhythmia⁹². Literature supports four mechanisms for the cardiotoxicity of cocaine.

13.1 Promotion of Intracoronary Thrombus Formation: Cocaine administration causes platelet aggregation and increases thromboxane - A₂ production which together contributes to the development of cardiomyopathy and left ventricular dysfunction⁹³.

13.2 Sympathomimetic Effect of Cocaine: Cocaine use results in activation of the beta-adrenergic receptor and increases myocardial contraction which finally leads to increased blood pressure and increased wall stress⁹³.

13.3 Increased Calcium Flux: Increased myocardial calcium flux into the myocardial cell causes membrane instability and arrhythmia⁹³.

13.4 Electrophysiological Effects: Use of cocaine causes prolongation of PR, QRS and QT duration that result into arterial fibrillation and tachycardia⁹³.

14. Anabolic - Androgenic Steroids and Cardio-Toxicity: Inappropriate use of anabolic steroid is associated with left ventricular hypertrophy⁹⁴. Anabolic steroid when administered, binds with androgenic receptors in the heart and in arteries⁴. Anabolic steroid causes hypertension, dyslipidemia atherosclerosis and impaired contraction-relaxation⁹⁵. Animal studies have shown the increased risk of cardiomyopathy and apoptosis in cardiac cells⁹⁶. Further, use of anabolic steroid causes the discrete release of calcium from sarcoplasmic reticulum

which additionally worsens the situation of arrhythmia and cardiomyopathy⁹⁵. Some other complications associated with the use of steroid includes endocardial and myocardial fibrosis, cardiac steatosis, myocardial necrosis, coagulation and coronary atheroma³.

15. Alcohol Abuse / Heavy Metals and Cardio-toxicity: Alcohol abuse primarily affects the central nervous system but it also exerts direct cardiotoxic effects^{97, 98}. There are documented evidence for dose-related cardiotoxicity for ethanol that includes left ventricular dysfunction and cardiomyopathy⁹⁹. Alcohol consumption affects the myocardial contractility, systolic-diastolic deregulations and abnormal rhythm¹⁰⁰. There are also documented evidence for dose-related cardiac depression¹⁰⁰. Ethanol when exceeds the limit of 75 mg/100 ml in plasma, the force of contraction reduces significantly¹⁰¹. Some heavy metals such as cadmium, lead, and cobalt also causes cardiotoxicity¹⁰². These heavy metal causes a structural change in cardiac cells, alter myocardial contraction and deregulation of some essential enzymes in heart muscles¹⁰².

15.1 Trigger of Torsade de pointis and Cardiotoxicity: QT prolongation is a standard parameter to study cardiac abnormalities¹⁰³. Further, prolongation of QT may be responsible for the sudden death and is called Torsade de Pointes¹⁰⁴. This type of arrhythmia is defined as the polymorphic ventricular tachycardia¹⁰⁵. Torsades de pointis are very complicated and serious situation which often shift to ventricular fibrillation¹⁰⁶. Drugs associated with increased risk of Torsade de Pointes are shown in **Table 3**¹⁰⁷.

TABLE 3: DRUGS ASSOCIATED WITH INCREASED RISK OF TORSADE DE POINTES¹⁰⁷

S. no.	Drugs	
1	Halofantrine	Probuocol
2	Amiodarone	Terfenadine
3	Arsenic trioxide	Quinidine
4	Astemizole	Pentamidine
5	Bepidil	Methadone
6	Chloroquine	Mesoridazine
7	Chlorpromazine	Ibutilide
8	Cisapride	Moxifloxacin
9	Haloperidol	Procainamide
10	Droperidol	Thioridazine
11	Sotalol	Sapofloxacin
12	Levomethadyl	Disopyramide
13	Thioridazine	Erythromycin
14	Vandetanib	Domperidone

CONCLUSION: Now-a-days cardiac complication is increasing day by day. Polypharmacy approach, on the other hand is responsible for the occurrence of secondary disorders such as hypertension and arrhythmia. There are many drugs which are co-administered with existing therapy and further worsen the cardiac complications. Beta blockers, calcium channel blockers, antiarrhythmic drugs, anticancer drugs and immunomodulatory drugs are routinely used by the clinician, thus appropriate monitoring is a prerequisite for the use of these drugs. Particularly in patients with left ventricular dysfunction, utmost precaution should be taken for cardiac toxicity of prescribed medicine. Although, drug - induced cardiomyopathy doesn't occur frequently, a regular monitoring is advised to prevent any such situation while using the discussed therapeutic agents.

ACKNOWLEDGEMENT: The authors would like to thank Department of Pharmacology, Jamia Hamdard for providing the facilities.

CONFLICT OF INTEREST: Nil

REFERENCES:

- Shin DD, Brandimarte F, De Luca L *et al.*: Review of current and investigational pharmacologic agents for acute heart failure syndromes. *The American journal of cardiology* 2007; 99: S4-S23.
- Kaiserová H: Preventing anthracycline cardiotoxicity: from iron chelation to carbonyl reductase inhibition 2017.
- Figueredo VM: Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. *The American journal of medicine* 2011; 124: 480-8.
- Klimas J: *Drug-Induced Cardiomyopathies*: INTECH Open Access Publisher 2012.
- Lee CS: Mechanisms of cardiotoxicity and the development of heart failure. *Critical care nursing clinics of North America* 2015; 27: 469-81.
- Becher PM, Jugdutt BI, Baugh J and Schmack B: *Experimental Heart Failure Models and Their Pathophysiological Characterization*. BioMed research international 2016.
- Silverstein D and Hopper K: *Small animal critical care medicine*: Elsevier Health Sciences 2014.
- Tripathi K: *Essentials of medical pharmacology*: JP Medical Ltd; 2013.
- McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM and Yellon DM: Anthracycline chemotherapy and cardiotoxicity. *Cardiovascular Drugs and Therapy* 2017; 1-13.
- Cagel M, Grotz E, Bernabeu E, Moreton MA and Chiappetta DA: Doxorubicin: nanotechnological overviews from bench to bedside. *Drug discovery today* 2017; 22: 270-81.
- Manivasagan P, Kang KH, Sivakumar K, Li-Chan EC, Oh HM and Kim SK: Marine actinobacteria: An important source of bioactive natural products. *Environmental toxicology and pharmacology* 2014; 38: 172-88.
- Cardinale D, Colombo A, Bacchiani G, *et al.*: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation* 2015; *Circulationaha*. 114.013777.
- Khouri MG, Klem I, Shenoy C, Sulpher J and Dent SF: *Screening and Monitoring for Cardiotoxicity During Cancer Treatment*. Cardio-Oncology: Springer 2017; 43-80.
- Wang L, Tan TC, Halpern EF *et al.*: Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline - based chemotherapy. *The American journal of cardiology* 2015; 116: 442-6.
- Angsutararux P, Luanpitpong S and Issaragrisil S: Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. *Oxidative medicine and cellular longevity* 2015.
- Popat R, Oakervee HE, Hallam S *et al.*: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. *British journal of haematology* 2008; 141: 512-6.
- Ichikawa Y, Ghanefar M, Bayeva M *et al.*: Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *The Journal of clinical investigation* 2014; 124:6 17.
- Outomuro D, Grana DR, Azzato F and Milei J: Adriamycin-induced myocardial toxicity: new solutions for an old problem? *International journal of cardiology* 2007; 117: 6-15.
- Münzel T, Gori T, Keane Jr JF, Maack C and Daiber A: Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. *European heart journal* 2015; 36: 2555-64.
- Šimůnek T, Štěrba M, Popelová O, Adamcová M, Hrdina R and Geršl V: Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. *Pharmacological Reports* 2009; 61: 154-71.
- Vejjongsang P and Yeh ET: Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. *Journal of the American College of Cardiology* 2014; 64: 938-45.
- Menna P and Salvatorelli E: Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview. *Chemotherapy* 2017; 62: 159-68.
- Goldberg MA, Antin JH, Guinan EC and Rapoport JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. *Blood* 1986; 68: 1114-8.
- Madondo MT, Quinn M and Plebanski M: Low dose cyclophosphamide: mechanisms of T cell modulation. *Cancer treatment reviews* 2016; 42: 3-9.
- Raj S, Franco VI and Lipshultz SE: Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. *Current treatment options in cardiovascular medicine* 2014; 16: 315.
- Feenstra J, Grobbee DE, Remme WJ and Stricker BHC: Drug-induced heart failure. *Journal of the American College of Cardiology* 1999; 33: 1152-62.
- Benbow SJ, Wozniak KM, Kulesh B, *et al.*: Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy. *Neurotoxicity Research* 2017; 1-12.

28. Chan JK, Brady MF, Penson RT, *et al.*: Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. *New England Journal of Medicine* 2016; 374: 738-48.
29. Vashishtha H and Ginsburg DS: Effects of Tip60 and Paclitaxel on Breast and Lung Cancer. *Clinical Laboratory Science* 2016; 29.
30. Spencer CM and Faulds D: Paclitaxel. *Drugs* 1994; 48: 794-847.
31. Rowinsky E and Donehower R: Paclitaxel (taxol) *N Engl J Med.* 1995; 332: 1004–1014. doi: 10.1056. NEJM199504133321507[PubMed][Cross Ref].
32. Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T and Thomssen C: Cardiotoxicity and oncological treatments. *Deutsches Ärzteblatt International* 2014; 111: 161.
33. Gianni L, Munzone E, Capri G *et al.*: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. *Journal of Clinical Oncology* 1995; 13: 2688-99.
34. White RJ and Durr FE: Development of mitoxantrone. *Investigational new drugs* 1985; 3: 85-93.
35. Shaikh AY, Suryadevara S, Tripathi A *et al.*: Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia - A Velocity Vector Imaging Analysis. *Echocardiography* 2016; 33: 1166-77.
36. Mather F, Simon R, Clark G and Von Hoff D: Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. *Cancer treatment reports* 1987; 71: 609.
37. Thomas SA, Grami Z, Mehta S and Patel K: Adverse effects of 5-fluorouracil: Focus on rare side effects. *Cancer Cell and Microenvironment* 2016; 3.
38. Altieri P, Murialdo R, Barisione C *et al.*: 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. *British Journal of Pharmacology* 2017.
39. Polk A, Vistisen K, Vaage-Nilsen M and Nielsen DL: A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. *BMC Pharmacology and Toxicology* 2014; 15: 47.
40. Lestuzzi C, Berretta M and De Paoli A: Capecitabine cardiotoxicity: How to limit life-threatening events. *International Journal of Cardiology* 2017; 229: 5.
41. Sato M and Park M: Case Report: Cytarabine-Induced Pericarditis and Pericardial Effusion. *The Medicine Forum* 2017; 10.
42. Lancellotti P, Moonen M and Jerusalem G: Predicting Reversibility of Anticancer Drugs-Related Cardiac Dysfunction: A New Piece to the Routine Use of Deformation Imaging. *Echocardiography* 2016; 33: 504-9.
43. Sharma A, Burrige PW, McKeithan WL *et al.*: High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. *Science translational medicine* 2017; 9: eaaf2584.
44. Gharwan H and Groninger H: Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. *Nature reviews Clinical oncology* 2016; 13: 209-27.
45. Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy D and Rennert G: Tyrosine kinase-targeting drugs-associated heart failure. *British Journal of Cancer* 2017.
46. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V and Ustun B: Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *The Lancet* 2007; 370: 851-8.
47. Palmer S, Vecchio M, Craig JC *et al.*: Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. *Kidney international* 2013; 84: 179-91.
48. Conrad SK, Catalano MC and Catalano G: The use of fluoxetine in a patient with Takotsubo cardiomyopathy. *Journal of Psychiatric Practice* 2016; 22: 234-8.
49. Glassman A, Bigger JT, Giardina E, Kantor S, Perel J and Davies M: Clinical characteristics of imipramine-induced orthostatic hypotension. *The Lancet* 1979; 313: 468-72.
50. Coupland C, Hill T, Morriss R, Moore M, Arthur A and Hippisley-Cox J: Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. *bmj* 2016; 352: i1350.
51. Nezafati MH, Vojdanparast M and Nezafati P: Antidepressants and cardiovascular adverse events: A narrative review. *ARYA atherosclerosis* 2015; 11: 295.
52. Fukushima N, Nanao K, Fukushima H, Namera A and Miura M: A neonatal prolonged QT syndrome due to maternal use of oral tricyclic antidepressants. *European journal of pediatrics* 2016; 175: 1129-32.
53. Ray WA, Meredith S, Thapa PB, Hall K and Murray KT: Cyclic antidepressants and the risk of sudden cardiac death. *Clinical Pharmacology and Therapeutics* 2004; 75: 234-41.
54. Amsterdam J, Brunswick D and Mendels J: The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. *Am J Psychiatry* 1980; 137: 653-62.
55. Isbister GK: Electrocardiogram changes and arrhythmias in venlafaxine overdose. *British journal of clinical pharmacology* 2009; 67: 572-6.
56. Rossman I and Veith RC: Depression in the elderly: Pharmacologic considerations in treatment. *Journal of the American Geriatrics Society* 1982; 30: 581-6.
57. Álamo C, López-Muñoz F, García-García P and García-Ramos S: Risk–benefit analysis of antidepressant drug treatment in the elderly. *Psychogeriatrics* 2014; 14: 261-8.
58. O’Leary OF, Dinan TG and Cryan JF: Faster, better, stronger: towards new antidepressant therapeutic strategies. *European journal of pharmacology* 2015; 753: 32-50.
59. Godfraind T: Calcium channel blockers in cardiovascular pharmacotherapy. *Journal of cardiovascular pharmacology and therapeutics* 2014; 19: 501-15.
60. Beevers D and Sleight P: Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? *BMJ: British Medical Journal* 1996; 312: 1143.
61. Whyte I, Buckley N and Dawson A: Calcium channel blockers. *Medicine* 2016; 44: 148-50.
62. Girouard C, Grégoire J-P, Poirier P and Moisan J: Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. *Medicine* 2017; 96.
63. Solomon R and McCord J: Medications to Avoid in Acute Decompensated Heart Failure. *Current Emergency and Hospital Medicine Reports* 2017; 5: 83-7.
64. Aurora L and McCord J: Drugs to Avoid in Acute Decompensated Heart Failure (ADHF): Contraindicated Medications and Interactions. *Short Stay Management of Acute Heart Failure: Springer*; 2017: 261-8.
65. Honerjäger P, Loibl E, Steidl I, Schönsteiner G and Ulm K: Negative inotropic effects of tetrodotoxin and seven class I antiarrhythmic drugs in relation to sodium channel blockade. *Naunyn-Schmiedeberg's archives of pharmacology* 1986; 332: 184-95.

66. Greene HL, Richardson DW, Hallstrom AP *et al.*: Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). *The American journal of cardiology* 1989; 63: 393-8.
67. Özkaya E and Yazganoglu KD: Class III Antiarrhythmic Drugs. *Adverse Cutaneous Drug Reactions to Cardiovascular Drugs*: Springer 2014; 123-8.
68. Driessen H, Bourgonje V, van Veen T and Vos M: New antiarrhythmic targets to control intracellular calcium handling. *Netherlands Heart Journal* 2014; 22: 198-213.
69. Jafib B, Doctor M, Panel D *et al.*: Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease, and acute liver injury: dronedarone versus amiodarone and other antiarrhythmics 2013.
70. Prins KW, Neill JM, Tyler JO, Eckman PM and Duval S: Effects of beta-blocker withdrawal in acute decompensated heart failure. *JACC: Heart Failure* 2015; 3: 647-53.
71. Pinnock C, Yip JL, Khawaja AP *et al.*: Topical Beta-Blockers and Cardiovascular Mortality: Systematic Review and Meta-Analysis with Data from the EPIC-Norfolk Cohort Study. *Ophthalmic Epidemiology* 2016; 23: 277-84.
72. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Choodnovskiy I and Avorn J: Topical glaucoma medications and cardiovascular risk in the elderly. *Clinical Pharmacology and Therapeutics* 1994; 55: 76-83.
73. Chen H, Ye L, Su J, *et al.*: Effects of different types of interferon on the expression of HCV replication-related microRNA. *Zhonghua yi xue za zhi* 2014; 94: 776-9.
74. Zimmerman S, Adkins D, Graham M, *et al.*: Case report: Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy 2009.
75. Ferreira L, Frade AF, Baron MA *et al.*: Interferon- γ and other inflammatory mediators in cardiomyocyte signaling during Chagas disease cardiomyopathy. *World journal of cardiology* 2014; 6: 782-90.
76. Sleijfer S, Bannink M, Van Gool AR, Kruit WH and Stoter G: Side effects of interferon- α therapy. *Pharmacy world and science* 2005; 27: 423-31.
77. Rochette L, Guenancia C, Gudjoncik A *et al.*: Anthracyclines / trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. *Trends in pharmacological sciences* 2015; 36: 326-48.
78. Tan MCC, Ortega-Legaspi JM, Cheng SF and Patton KK: Acute myocarditis following high-dose interleukin-2 treatment. *Journal of Cardiology Cases* 2017; 15: 28-31.
79. Deventer K, Van Eenoo P and Delbeke F: Screening for amphetamine and amphetamine-type drugs in doping analysis by liquid chromatography / mass spectrometry. *Rapid communications in mass spectrometry* 2006; 20: 877-82.
80. Samanin R: Central mechanisms of anorectic drugs. *Medicinal Chemistry Advances: Proceedings of the Seventh International Symposium on Medicinal Chemistry, Torremolinos, Spain*. Elsevier 1980; 2016; 271.
81. Hutson PH, Tarazi FI, Madhoo M, Slawewski C and Patkar AA: Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders. *Pharmacology and therapeutics* 2014; 143: 253-64.
82. Turnipseed SD, Richards JR, Kirk JD, Diercks DB and Amsterdam EA: Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. *The Journal of emergency medicine* 2003; 24: 369-73.
83. Wijetunga M, Seto T, Lindsay J and Schatz I: Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? *Journal of Toxicology: Clinical Toxicology* 2003; 41: 981-6.
84. Yeo KK, Wijetunga M, Ito H *et al.*: The association of methamphetamine use and cardiomyopathy in young patients. *The American journal of medicine* 2007; 120: 165-71.
85. Solís-Olivares CA and Ramírez-García HA: Amphetamine-related dilated cardiomyopathy: a growing phenomenon. *Case report. Rev Mex Cardiol* 2017; 28: 35-9.
86. Bolton JL, Trush MA, Penning TM, Dryhurst G and Monks TJ: Role of quinones in toxicology. *Chemical research in toxicology* 2000; 13: 135-60.
87. Aniszewski T: *Alkaloids: Chemistry, Biology, Ecology, and Applications*: Elsevier 2015.
88. Braam C: *From Coca to Cocaine. Shooting Up: A Short History of Drugs and War* 2016; 91.
89. Sable H, Miller M, Nelms J *et al.*: Behavioral pharmacology of cocaine and amphetamine in rats perinatally exposed to polychlorinated biphenyls (PCBs). *Neurotoxicology and Teratology* 2014; 88.
90. Pallavi R, Talebi S, Hassen G, Visco F and Popis-Matejak B: 1259: Cocaine Induced Cardiotoxicity. *Critical Care Medicine* 2014; 42: A1654.
91. Liaudet L, Calderari B and Pacher P: Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. *Heart failure reviews* 2014; 19: 815-24.
92. Maraj S, Figueredo VM and Lynn Morris D: Cocaine and the heart. *Clinical cardiology* 2010; 33: 264-9.
93. Awtry EH and Philippides GJ: Alcoholic and cocaine-associated cardiomyopathies. *Progress in cardiovascular diseases* 2010; 52: 289-99.
94. Giannotti S, Ghilardi M, Dell'Osso G, Bugelli G and Guido G: Left ventricular hypertrophy and spontaneous rupture of the Achilles tendon after anabolic steroids in bodybuilder. *European Orthopaedics and Traumatology* 2014; 5: 363-5.
95. Tsitsimpikou C: Cardiotoxicity of anabolic steroids; animal case study of oral turinabol and methanabol. *Toxicology Letters* 2014; S21.
96. Shamloul RM, Aborayah AF, Hashad A and Abd-Allah F: Anabolic steroids abuse-induced cardiomyopathy and ischaemic stroke in a young male patient. *BMJ case reports* 2014; bcr2013203033.
97. Gardner JD and Mouton AJ: Alcohol effects on cardiac function. *Comprehensive Physiology* 2015.
98. Gardenhire DS: *Drugs Affecting the Central Nervous System*. *Rau's Respiratory Care Pharmacology-E-Book* 2015; 330.
99. Wang Y, Li G, Sun Y, Shan G, Xu R and Guo L: Left ventricular strain and rotation by 2-D speckle tracking echocardiography identify early alcoholic cardiomyopathy. *Ultrasound in medicine and biology* 2016; 42: 1741-9.
100. Fernández-Solà J: Cardiovascular risks and benefits of moderate and heavy alcohol consumption. *Nature Reviews Cardiology* 2015; 12: 576-87.
101. Knochel JP: Cardiovascular effects of alcohol. *Annals of internal medicine* 1983; 98: 849-54.
102. Oyinloye BE, Ajiboye BO, Ojo OA, Nwozo SO and Kappo AP: Cardioprotective and antioxidant influence of aqueous extracts from *Sesamum indicum* seeds on oxidative stress induced by cadmium in wistar rats. *Pharmacognosy magazine* 2016; 12: S170.

103. Keirns J, Desai A, Kowalski D, et al.: QT interval Shortening with Isavuconazole: *In vitro* and *in vivo* Effects on Cardiac Repolarization. *Clinical Pharmacology and Therapeutics* 2017.
104. Schlit AF, Delaunoy A, Colomar A et al.: Risk of QT prolongation and torsades de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. *Pharmacology Research and Perspectives* 2017; 5.
105. Passman R and Kadish A: Polymorphic ventricular tachycardia, long QT syndrome, and torsades de pointes. *Medical Clinics of North America* 2001; 85: 321-41.
106. Weiss JN, Garfinkel A, Karagueuzian HS et al.: Perspective: a dynamics-based classification of ventricular arrhythmias. *Journal of molecular and cellular cardiology* 2015; 82: 136-52.
107. Salvi V, Karnad DR, Panicker GK and Kothari S: Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. *British journal of pharmacology* 2010; 159: 34-48.

How to cite this article:

Iqbal A, Haque SE, Sharma S, Ansari MA, Khan V and Iqbal MK: Clinical updates on drug-induced cardiotoxicity. *Int J Pharm Sci Res* 2018; 9(1): 16-26. doi: 10.13040/IJPSR.0975-8232.9(1).16-26.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)